• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.阿杜卡努单抗在降低淀粉样蛋白的同时产生了具有临床意义的益处。
Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.
2
Substantial Doubt Remains about the Efficacy of Anti-Amyloid Antibodies.抗淀粉样蛋白抗体的疗效仍存在很大疑问。
J Alzheimers Dis. 2024;97(2):567-572. doi: 10.3233/JAD-231198.
3
Lecanemab, Aducanumab, and Gantenerumab - Binding Profiles to Different Forms of Amyloid-Beta Might Explain Efficacy and Side Effects in Clinical Trials for Alzheimer's Disease.仑卡奈单抗、阿杜卡玛单抗和加内替单抗——对不同形式的淀粉样蛋白-β的结合谱可能解释了阿尔茨海默病临床试验中的疗效和副作用。
Neurotherapeutics. 2023 Jan;20(1):195-206. doi: 10.1007/s13311-022-01308-6. Epub 2022 Oct 17.
4
How promising are the latest monoclonal antibodies targeting amyloid-β for the treatment of early Alzheimer's disease?针对淀粉样蛋白-β的最新单克隆抗体治疗早期阿尔茨海默病的前景如何？
Expert Opin Emerg Drugs. 2024 Mar;29(1):35-43. doi: 10.1080/14728214.2024.2304059. Epub 2024 Jan 12.
5
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.对我有什么好处？在早期阿尔茨海默病中，情境化评估 LeCanemab、Donanemab 和其他抗β-淀粉样蛋白单克隆抗体的潜在临床影响。
eNeuro. 2024 Sep 27;11(9). doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.
6
Talking points for physicians, patients and caregivers considering Aduhelm® infusion and the accelerated pathway for its approval by the FDA.供考虑使用阿杜海姆（Aduhelm®）输液疗法及其通过美国食品药品监督管理局（FDA）加速审批途径的医生、患者及护理人员的谈话要点。
Mol Neurodegener. 2021 Nov 4;16(1):74. doi: 10.1186/s13024-021-00490-z.
7
Comparative Efficacy, Tolerability, and Acceptability of Donanemab, Lecanemab, Aducanumab, Melatonin, and Aerobic Exercise for a Short Time on Cognitive Function in Mild Cognitive Impairment and Mild Alzheimer's Disease: A Systematic Review and Network Meta-Analysis.多奈单抗、莱卡奈单抗、阿杜卡单抗、褪黑素及有氧运动对轻度认知障碍和轻度阿尔茨海默病认知功能短期影响的疗效、耐受性及可接受性比较：一项系统评价与网状Meta分析
J Alzheimers Dis. 2024;98(3):825-835. doi: 10.3233/JAD-230911.
8
Potential impact of unblinding on observed treatment effects in Alzheimer's disease trials.阿尔茨海默病临床试验中揭盲对观察到的治疗效果的潜在影响。
Alzheimers Dement. 2024 Apr;20(4):3119-3125. doi: 10.1002/alz.13690. Epub 2024 Feb 21.
9
Comparative efficacy, tolerability and acceptability of donanemab, lecanemab, aducanumab and lithium on cognitive function in mild cognitive impairment and Alzheimer's disease: A systematic review and network meta-analysis.在轻度认知障碍和阿尔茨海默病患者中，比较 donanemab、lecanemab、aducanumab 和锂对认知功能的疗效、耐受性和可接受性：一项系统评价和网络荟萃分析。
Ageing Res Rev. 2024 Feb;94:102203. doi: 10.1016/j.arr.2024.102203. Epub 2024 Jan 20.
10
Aducanumab, gantenerumab, BAN2401, and ALZ-801-the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval.阿杜卡奴单抗、根特纳单抗、BAN2401 和 ALZ-801——用于治疗阿尔茨海默病的首批靶向淀粉样蛋白药物，具有近期获批的潜力。
Alzheimers Res Ther. 2020 Aug 12;12(1):95. doi: 10.1186/s13195-020-00663-w.

引用本文的文献

1
Development and validation of a combined clinical and MRI-based biomarker model to differentiate mild cognitive impairment from mild Alzheimer's disease.一种基于临床和MRI的联合生物标志物模型的开发与验证，用于区分轻度认知障碍和轻度阿尔茨海默病。
PCN Rep. 2025 Jun 26;4(2):e70134. doi: 10.1002/pcn5.70134. eCollection 2025 Jun.
2
Navigating the introduction of anti-amyloid therapy in Europe: a position statement by individual members of the EADC.欧洲抗淀粉样蛋白疗法引入的导航：欧洲阿尔茨海默病协作组个别成员的立场声明
Alzheimers Res Ther. 2025 May 24;17(1):116. doi: 10.1186/s13195-025-01766-y.
3
[F]Mefway: Imaging Serotonin 5HT Receptors in Human Postmortem Alzheimer's and Parkinson's Disease Anterior Cingulate. Potential Applications to Human Positron Emission Tomography Studies.[F]梅夫韦：人类死后阿尔茨海默病和帕金森病前扣带回中5-羟色胺5HT受体的成像。在人类正电子发射断层扫描研究中的潜在应用。
Biomolecules. 2025 Apr 16;15(4):592. doi: 10.3390/biom15040592.
4
Measuring time saved in Alzheimer's disease: What is a meaningful slowing of progression?衡量阿尔茨海默病中节省的时间：有意义的疾病进展减缓是怎样的？
Alzheimers Dement (N Y). 2025 Apr 11;11(2):e70081. doi: 10.1002/trc2.70081. eCollection 2025 Apr-Jun.
5
Could immunotherapy and regulatory T cells be used therapeutically to slow the progression of Alzheimer's disease?免疫疗法和调节性T细胞能否用于治疗以减缓阿尔茨海默病的进展？
Brain Commun. 2025 Feb 25;7(2):fcaf092. doi: 10.1093/braincomms/fcaf092. eCollection 2025.
6
Neuroprotection by chronic administration of Fluoroethylnormemantine (FENM) in mouse models of Alzheimer's disease.在阿尔茨海默病小鼠模型中，长期给予氟乙基去甲美金刚（FENM）的神经保护作用。
Alzheimers Res Ther. 2025 Jan 6;17(1):7. doi: 10.1186/s13195-024-01648-9.
7
From Fundamentals to Innovation in Alzheimer's Disease: Molecular Findings and Revolutionary Therapies.从阿尔茨海默病的基础到创新：分子发现和革命性疗法。
Int J Mol Sci. 2024 Nov 16;25(22):12311. doi: 10.3390/ijms252212311.
8
ABTrans: A Transformer-based Model for Predicting Interaction between Anti-Aβ Antibodies and Peptides.ABTrans：一种基于Transformer的预测抗Aβ抗体与肽相互作用的模型。
Interdiscip Sci. 2025 Mar;17(1):140-152. doi: 10.1007/s12539-024-00664-5. Epub 2024 Oct 28.
9
The AlzMatch Pilot Study - Feasibility of Remote Blood Collection of Plasma Biomarkers for Preclinical Alzheimer's Disease Trials.阿尔茨海默病匹配先导研究 - 远程采集用于临床前阿尔茨海默病试验的血浆生物标志物的可行性。
J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi: 10.14283/jpad.2024.101.
10
What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease.对我有什么好处？在早期阿尔茨海默病中，情境化评估 LeCanemab、Donanemab 和其他抗β-淀粉样蛋白单克隆抗体的潜在临床影响。
eNeuro. 2024 Sep 27;11(9). doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.

本文引用的文献

1
A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody.一项针对早期阿尔茨海默病的仑卡奈单抗（抗 Aβ 原纤维抗体）的随机、双盲、2b 期概念验证临床试验。
Alzheimers Res Ther. 2021 Apr 17;13(1):80. doi: 10.1186/s13195-021-00813-8.
2
Evaluation of Aducanumab for Alzheimer Disease: Scientific Evidence and Regulatory Review Involving Efficacy, Safety, and Futility.阿杜卡努单抗治疗阿尔茨海默病的评估：涉及疗效、安全性和无效性的科学证据与监管审查
JAMA. 2021 May 4;325(17):1717-1718. doi: 10.1001/jama.2021.3854.
3
Donanemab in Early Alzheimer's Disease.多奈单抗用于早期阿尔茨海默病
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.
4
Open Peer Commentary to "Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE Trials as reported by Biogen December 2019".对《未能证明阿杜卡单抗的疗效：对渤健公司2019年12月报告的EMERGE和ENGAGE试验的分析》的公开同行评论
Alzheimers Dement. 2021 Apr;17(4):702-703. doi: 10.1002/alz.12235. Epub 2020 Nov 1.
5
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.甘特纳珠单抗可减少前驱期至中度阿尔茨海默病患者的淀粉样蛋白-β斑块：一项 PET 亚研究中期分析。
Alzheimers Res Ther. 2019 Dec 12;11(1):101. doi: 10.1186/s13195-019-0559-z.
6
The "rights" of precision drug development for Alzheimer's disease.阿尔茨海默病精准药物研发的“权利”。
Alzheimers Res Ther. 2019 Aug 31;11(1):76. doi: 10.1186/s13195-019-0529-5.
7
What matters to people with memory problems, healthy volunteers and health and social care professionals in the context of developing treatment to prevent Alzheimer's dementia? A qualitative study.对于有记忆问题的人、健康志愿者以及健康和社会保健专业人员而言，在开发预防阿尔茨海默病痴呆症的治疗方法方面，什么是重要的？一项定性研究。
Health Expect. 2019 Jun;22(3):504-517. doi: 10.1111/hex.12876. Epub 2019 Feb 27.
8
Structural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β.淀粉样β聚集物形式选择的 aducanumab 的结构和动力学基础。
Sci Rep. 2018 Apr 23;8(1):6412. doi: 10.1038/s41598-018-24501-0.
9
NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.NIA-AA 研究框架：迈向阿尔茨海默病的生物学定义。
Alzheimers Dement. 2018 Apr;14(4):535-562. doi: 10.1016/j.jalz.2018.02.018.
10
The antibody aducanumab reduces Aβ plaques in Alzheimer's disease.阿杜卡努单抗可减少阿尔茨海默病中的 Aβ 斑块。
Nature. 2016 Sep 1;537(7618):50-6. doi: 10.1038/nature19323.

Aducanumab produced a clinically meaningful benefit in association with amyloid lowering.

作者信息

Cummings Jeffrey, Aisen Paul, Lemere Cynthia, Atri Alireza, Sabbagh Marwan, Salloway Stephen

机构信息

Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV), Las Vegas, NV, USA.

University of Southern California, San Diego, CA, USA.

出版信息

Alzheimers Res Ther. 2021 May 10;13(1):98. doi: 10.1186/s13195-021-00838-z.

DOI:10.1186/s13195-021-00838-z
PMID:33971962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8111757/
Abstract
摘要